RecruitingPhase 2NCT06174220

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Sponsor

Hamilton Health Sciences Corporation

Enrollment

120 participants

Start Date

Mar 21, 2025

Study Type

INTERVENTIONAL

Conditions

Arrhythmogenic Cardiomyopathy Arrhythmogenic Right Ventricular Cardiomyopathy

Summary

The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Tideglusib for people with arrhythmogenic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTideglusib

Tideglusib 1g po daily

DRUGPlacebo

Matching placebo 1g po daily

Locations(17)

University of Calgary

Calgary, Alberta, Canada

University of British Columbia

Vancouver, British Columbia, Canada

Victoria Cardiac Arrhythmia Trials Inc.

Victoria, British Columbia, Canada

NL Health Services

St. John's, Newfoundland and Labrador, Canada

Nova Scotia Health

Halifax, Nova Scotia, Canada

Hamilton General Hospital

Hamilton, Ontario, Canada

Kingston General Hospital

Kingston, Ontario, Canada

London Health Sciences Centre

London, Ontario, Canada

Newmarket Electrophysiologist Research Group 'NERG'

Newmarket, Ontario, Canada

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

Heart Health Institute Research Inc

Scarborough Village, Ontario, Canada

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

St. Michael's Hospital

Toronto, Ontario, Canada

Montreal Heart Institute

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Hopital du Sacré-Coeur de Montréal

Montreal, Quebec, Canada

University Institute of Cardiology and Pneumology of Quebec

Québec, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06174220

Related Trials

Pediatric Cardiomyopathy Mutation Analysis

NCT024320921 location

FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))

NCT075636601 location

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(17)

Related Trials

Pediatric Cardiomyopathy Mutation Analysis

FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))

Mayo AVC Registry and Biobank

Arrhythmogenic Activity During Exercise in ARVC Patients

The Application of T1 Mapping in Real-World